Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access & Reimbursement

Set Alert for Market Access & Reimbursement

Latest From Market Access

UK NICE Knock Back For Janssen’s ‘Game-Changing’ Darzalex Combo

Draft guidance from the health technology assessment body, NICE, says that while Darzalex in combination with two other drugs is an innovative therapy for previously treated multiple myeloma, there is not enough long-term data to support its use on NHS England.

Health Technology Assessment Reimbursement

Long-Awaited Brexit White Paper Lays Out UK’s Plans For Medicines Regulation

The UK government has finally published its white paper on the UK’s future relationship with the EU following Brexit, to the relief of the pharmaceutical industry.
Brexit Regulation

Vertex Refuses To Back Down On England Orkambi Deal

Vertex is staunchly defending its cystic fibrosis portfolio-based reimbursement deal rejected by NHS England and has called on the UK’s prime minister to intervene. The company says similar deals have worked well in Ireland and Sweden.

Europe United Kingdom

CMS' Verma Touts Value-Based Payments After Cancellation Of Pilot For Novartis' Kymriah

'It's not for every medication,' CMS administrator says, but agency continues to explore how to apply value-based pricing.

Medicare ImmunoOncology

‘Unacceptable’ Medicine Shortages Lead French Senate To Set Up Task Force

Medicine shortages are under scrutiny at national and EU level. In France, a newly established Senate task force is hearing evidence from a range of stakeholders including industry and regulators.

Distribution Manufacturing

CAR-T Drugs' Patient-Reported Outcomes To Be Focus Of MedCAC Meeting

Focus is in line with past US Medicare advisory panel meetings on other diseases.

Medicare ImmunoOncology
See All
UsernamePublicRestriction

Register